BETAAccess all features while we're in beta! Some features may become paid later.Send feedback →
vpside

AVTX

Avalo Therapeutics, Inc.
Nasdaq · Pharmaceutical preparations (SIC 2834) · FY ends 31 Dec

Revenue, quarterly

$59000−69.3% year on year
$15M$10M$5M$0
Q1 ’21Q2 ’22Q3 ’23Q3 ’24Q4 ’25
Company filings · 10-K filed 23 Mar 2026 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

182.0%+176.4 pp year on year
200%100%0%
Q4 ’19Q1 ’21Q2 ’22Q2 ’23Q3 ’24
Company filings · 10-Q filed 6 Nov 2025 · TTM = last four quartersvpside.com

Cash and cash equivalents, quarter-end

$85M+101.9% year on year
$150M$100M$50M$0
Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26
Company filings · 10-Q filed 6 Aug 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

−$49M
$25M$0−$25M−$50M−$75M
Q1 ’20Q2 ’21Q3 ’22Q3 ’23Q4 ’24
Company filings · 10-K filed 23 Mar 2026 · TTM = last four quartersvpside.com
Chart 05 is empty
Chart 06 is empty